MagVenture FDA Clearance for Adolescent Depression

MagVenture has achieved a major milestone in mental health care: FDA clearance for the treatment of Major Depressive Disorder (MDD) in adolescents aged 15 to 21. > This webinar provides a comprehensive overview of how this clearance changes the landscape for pediatric psychiatry. Experts discuss the safety profile, efficacy, and practical considerations for treating younger populations with non-invasive neuromodulation. Key Webinar Highlights:. Clinical Evidence: Review of the data supporting the use of rTMS as a safe and effective adjunct or alternative to pharmacotherapy for teens., The "Why" for Adolescents: Addressing the urgent need for new MDD treatment options in a population where medication side effects and treatment resistance are significant challenges., Protocol Specifics: Insights into motor threshold determination and coil positioning tailored for adolescent neuroanatomy., Practice Implementation: How to communicate the benefits of TMS to parents and young patients, and navigate the insurance landscape for this newly cleared age group. This session is essential for child and adolescent psychiatrists, clinical directors, and TMS technicians looking to expand their practice's reach and impact.